INTERNATIONAL STEM CELL CORP Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes and other financial information included elsewhere herein. This information should also be read in conjunction with our audited historical consolidated financial statements which are included in our Form 10-K for the fiscal year ended December 31, 2008. The discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, expectations and intentions. Our actual results may differ significantly from management's expectations. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion only represents our management's best present assessment. Overview We were originally incorporated in Delaware on June 7, 2005 as BTHC III, Inc. to effect the reincorporation of BTHC III, LLC, a Texas limited liability company, mandated by a plan of reorganization. Pursuant to the plan of reorganization, an aggregate of 500,000 shares of our common stock were issued to holders of administrative and tax claims and unsecured debt, of which 350,000 shares were issued to Halter Financial Group. The plan of reorganization required BTHC III, Inc. to consummate a merger or acquisition prior to June 20, 2007. Until the Share Exchange Agreement described below, BTHC III, Inc. conducted no operations. In October 2006, BTHC III, Inc. affected a 4.42-for-one stock split with respect to the outstanding shares of common stock. On December 28, 2006, pursuant to a Share Exchange Agreement, BTHC III, Inc. issued 33,156,502 shares of common stock, representing ap...
Click here to read the whole Article (external link)

INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS International Stem Cell Corporation (ISCO) has made important strategic changes in its management team. Dr. Andrey Semechkin has agreed to become Chief Executive Officer, effective as of November 15, 2009, and the company has hired a seasoned biotech executive, Brian Lundstrom, to be its new President. Kenneth Aldrich, who has been serving as both CEO and Chairman since the death of the company's former CEO in January 2008, will remain as Chairman of the Board. Dr. Semechkin, who is already serving as a Director and as Executive Vice President of ISCO, has more than 20 years of experience in successfully creating and developing companies in different industries and scientific sectors, both in his native Russia and internationally, including the US. He is a member of the prestigious Russian Academy of Science, specializing in management theory, strategic planning and system analysis. He is also the author of several books in those fields and in 2005 was awarded the Russian Federation Government Award in Science and Technology in recognition of his scientific achievements. Mr. Lundstrom accepted the position of President on November 5, 2009. Mr. Lundstrom has extensive experience in both domestic and international biopharmacetuical product development. Mr. Lundstrom is 47 years of age and trained in immunology, molecular biology, finance and marketing in Europe and the US. He brings to ISCO 23 years of clinical and commercial development and corporate transactional experience from R&D-driven, predominantly publicly traded and commercially operating companies, including Immuntech (1986-1989), Novo Nordisk (1990-1997), OGS (1998-2000), SangStat/Genzyme (2000-2004), ACADIA (2004-2008) , where he served as Senior Vice President of Business and Commercial Development, and Brexys (2008-2009), where he served as...
Click here to read the whole Article (external link)

International Stem Cell Corporation Announces Strategic Enhancement of its Management Team

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO - News), www.internationalstemcell.com announced today that it had made important strategic changes in its management team to leverage its growing opportunities in the therapeutic and research product markets. The Company’s current Board Member and Executive Vice-President, Dr. Andrey Semechkin, will become CEO on November 15, 2009, and Brian Lundstrom, an experienced biopharmaceutical executive, has joined the Company as President. Kenneth Aldrich will remain as Chairman of the Board and continue the active role he has played since the founding of the Company. Jeffrey Janus will remain as Senior Vice President of ISCO and CEO of its subsidiary, Lifeline Cell Technology.Commenting on these management changes, Mr. Aldrich said, “We have been searching for many months to find exactly the right combination of skills and experience to replace what we lost with the death of our former CEO, Jeff Krstich, in 2008. The wait has been well worthwhile. ...
Click here to read the whole Article (external link)

International Stem Cell Corporation and Reproductive Medicine Associates of New York Announce Breakthrough in Creating an Abundant and Ethical New Source of Human Pluripotent Stem Cells

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo. This discovery vastly increases the opportunity for ISCO to create new stem cell lines and hastens the time when “banks”...
Click here to read the whole Article (external link)

CEO Interview: International Stem Cell Corporation - Kenneth C. Aldrich

67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology Companies include: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cel...
Click here to read the whole Article (external link)

INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ

Show all filings for INTERNATIONAL STEM CELL CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for INTERNATIONAL STEM CELL CORP 19-Oct-2009Entry into a Material Definitive Agreement, Unregistered Sale of Equ Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informat...
Click here to read the whole Article (external link)

International Stem Cell Corporation, Through Its Subsidiary Lifeline Cell Technology, Announces the Launch and Sale of New Products into the Human Cell Research Market

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com), announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to min...
Click here to read the whole Article (external link)

International Stem Cell Corporation and Absorption Systems Announce Potential Stem Cell Alternative to Live Animal Testing for Corneal Damage

OCEANSIDE, Calif. & EXTON, Pa.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO)(www.internationalstemcell.com), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with ...
Click here to read the whole Article (external link)

INTERNATIONAL STEM CELL CORP Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

INTERNATIONAL STEM CELL CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements a

Show all filings for INTERNATIONAL STEM CELL CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K/A for INTERNATIONAL STEM CELL CORP 20-Aug-2009Entry into a Material Definitive Agreement, Financial Statements a Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All inform...
Click here to read the whole Article (external link)